表紙
市場調査レポート

肺高血圧症の世界市場:2015〜2019年

Pulmonary Hypertension - Global Market Research 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 341190
出版日 ページ情報 英文 65 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
肺高血圧症の世界市場:2015〜2019年 Pulmonary Hypertension - Global Market Research 2015-2019
出版日: 2015年09月30日 ページ情報: 英文 65 Pages
概要

肺高血圧症は肺から心臓に非酸素化血液を送る肺動脈に影響を及ぼす疾患です。肺動脈の狭窄や閉塞が肺高血圧を引き起こします。重症になるまで症状が現れません。主な原因は肺気腫、結合組織障害、肺内の血栓、睡眠時無呼吸などです。世界の肺高血圧症市場は2014〜2019年にかけCAGR2.92%で拡大すると予測されています。

当レポートでは、世界の肺高血圧症市場の現況と2015〜2019年の成長見通しについて調査し、市場規模、収益動向、製品別、地域別動向、および主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

第5章 市場環境

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第6章 パイプラインポートフォリオ

第7章 製剤別市場セグメンテーション

  • 経口
  • 注入
  • 吸入

第8章 作用機序別市場セグメンテーション

  • エンドセリン受容体拮抗薬
  • プロスタサイクリン類似体
  • ホスホジエステラーゼ阻害剤
  • 可溶性グアニル酸シクラーゼ

第9章 地域別セグメンテーション

第10章 市場促進因子

  • 肺高血圧症の発症率上昇
  • 患者支援プログラム
  • 新たな疾患調節療法
  • アンメットニーズ

第11章 市場促進因子の影響

第12章 市場の課題

  • 特許の失効
  • 患者適合性の低さ
  • ベンダー間の激しい競争

第13章 促進因子と課題の影響

第14章 市場動向

  • 併用療法への注目
  • 高血圧への意識向上
  • 戦略的提携

第15章 ベンダー環境

  • 競合シナリオ
  • 最新動向
  • 合併・買収
  • 市場シェア分析:2014年
  • その他の注目すべきベンダー

第16章 主要ベンダー分析

  • Actelion Pharmaceuticals
  • Bayer HealthCare
  • GSK
  • United Therapeutics

第17章 付録

第18章 Technavioについて

図表

目次
Product Code: IRTNTR7554

About pulmonary hypertension

Pulmonary hypertension is a rare disorder that affects the pulmonary arteries carrying deoxygenated blood to the lungs from the heart. The narrowing or blockage of pulmonary arteries will lead to pulmonary hypertension. Symptoms of the disease do not occur until the disease becomes severe. Certain causes of pulmonary hypertension include emphysema, connective tissue disorders, blood clots in lungs, and sleep apnea. Pulmonary hypertension may sometimes lead to several chronic illnesses, such as kidney failure (renal failure), heart failure, aneurysm, heart attack, or, stroke. Endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase inhibitors, and sGC stimulators are popular drug therapeutic classes available for the treatment of pulmonary hypertension.

Technavio's analysts forecast the global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global pulmonary hypertension market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of pulmonary hypertension.

Technavio's report, Global Pulmonary Hypertension Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

Key vendors

  • Actelion
  • Bayer
  • GlaxoSmithKline
  • United Therapeutics

Other Prominent Vendors

  • Aires Pharmaceuticals
  • Arena Pharmaceuticals
  • Bial
  • DEKA
  • Dong-A ST
  • Gilead
  • Merck
  • Northern Therapeutics
  • Novartis
  • Pfizer
  • PhaseBio

Key market driver

  • Growing incidence of pulmonary hypertension
  • For a full, detailed list, view our report

Key market challenge

  • Patent expiry
  • For a full, detailed list, view our report

Key market trend

  • Increased focus on combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Pipeline portfolio

  • Key information of pipeline candidates

PART 07: Market segmentation by type of formulation

  • Oral
  • Injection
  • Inhalation

PART 08: Market segmentation by mechanism of action

  • Endothelin receptor antagonist
  • Prostacyclin analogs
  • Phosphodiesterase inhibitors
  • Soluble guanylate cyclase stimulators

PART 09: Geographical segmentation

PART 10: Market drivers

  • Increase in incidence of pulmonary hypertension
  • Patient assistance programs
  • New disease-modifying therapies
  • Unmet medical needs

PART 11: Impact of drivers

PART 12: Market challenges

  • Patent expiry
  • Poor patient compliance
  • Intense competition among vendors

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Increased focus on combination therapies
  • Increase in awareness of hypertension
  • Strategic alliances

PART 15: Vendor landscape

  • Competitive scenario
  • Key news
  • Mergers and acquisitions
  • Market share analysis 2014
  • Other prominent vendors

PART 16: Key vendor analysis

  • Actelion Pharmaceuticals
  • Bayer HealthCare
  • GSK
  • United Therapeutics

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global pulmonary hypertension market: 2014-2019 ($ billions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Pipeline portfolio
  • Exhibit 05: Market segmentation by type of formulation
  • Exhibit 06: Market segmentation by type of formulation 2014
  • Exhibit 07: Market segmentation by mechanism of action
  • Exhibit 08: Market segmentation by mechanism of action 2014
  • Exhibit 09: Market segmentation by region 2014
  • Exhibit 10: Impact of drivers
  • Exhibit 11: Revatio sales in the US 2011-2014 ($ millions)
  • Exhibit 12: Impact of drivers and challenges
  • Exhibit 13: Actelion Pharmaceuticals : Key takeaways
  • Exhibit 14: Tracleer: Global sales 2011-2014 ($ billions)
  • Exhibit 15: Opsumit: Global sales 2013-2015 H1 ($ millions)
  • Exhibit 16: Ventavis: Global sales 2011-2014 ($ millions)
  • Exhibit 17: Veletri: Global sales 2011-2014 ($ millions)
  • Exhibit 18: United Therapeutics: Key takeaways
  • Exhibit 19: Remodulin: Global sales 2011-2014 ($ millions)
  • Exhibit 20: Tyvaso: Global sales 2011-2014 ($ millions)
  • Exhibit 21: Adcirca: Global sales 2011-2014 ($ millions)
  • Exhibit 22: Orenitram: Global sales 2014-2015 H2 ($ millions)
  • Exhibit 23: GlaxoSmithKline: Key takeaways
  • Exhibit 24: Flolan: Global sales 2012-2013 ($ millions)
  • Exhibit 25: Bayer: Key takeaways
  • Exhibit 26: Adempas: Global sales 2013-2014 ($ millions)
  • Exhibit 27: Actelion Pharmaceuticals: Product segmentation
  • Exhibit 28: Actelion Pharmaceuticals: Business segmentation by revenue 2014
  • Exhibit 29: Actelion Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 30: Actelion Pharmaceuticals: Geographical segmentation by revenue 2014
  • Exhibit 31: United Therapeutics: Product segmentation by revenue 2014
  • Exhibit 32: United Therapeutics: Product segmentation by revenue 2014 ($ millions)
  • Exhibit 33: United Therapeutics: Geographical segmentation by revenue 2014
Back to Top